Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of E-islet 01 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia
This study will evaluate the safety, tolerability and efficacy of E-islet 01 in participants with Type 1 diabetes mellitus (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia
100 Clinical Results associated with EndoCell Therapeutics, Inc.
0 Patents (Medical) associated with EndoCell Therapeutics, Inc.
100 Deals associated with EndoCell Therapeutics, Inc.
100 Translational Medicine associated with EndoCell Therapeutics, Inc.